Ⅲ期结肠腺癌患者ERCC1基因多态性的检测及其与奥沙利铂化疗效果的关系

Relationship between ERCC1 gene polymorphism and oxaliplatin chemotherapy in patients with stage Ⅲ colon adenocarcinoma

目的了解Ш期结肠腺癌患者ERCC1基因多态性及其与奥沙利铂化疗效果的关系。方法收集经病理学确诊的Ш期结肠腺癌患者85例,PCR检测ERCC1基因型;采用标准mFOLFOX6方案化疗12疗程,观察5a生存率和无疾病进展率。结果 85例中C/C基因型频率为38.8%,T/T+C/T基因型频率为61.2%。C/C基因型患者5a生存率和无疾病进展率分别为76.5%和72.1%,T/T+C/T基因型5年生存率和无疾病进展率分别为53.8%和46.1%,两组差异均有统计学意义(P<0.05)。结论 ERCC1C/C基因型Ш期结肠腺癌患者对奥沙利铂化疗方案具有较好疗效。

Objective To observe the relationship between ERCC1 gene polymorphism and oxaliplatin chemotherapy in patients with stage Ⅲ colon adenocarcinoma. Methods ERCC1 genotypes were determined by PCR in 85 patients with stage Ⅲ colon adenocarcinoma. All patients were treated with standard mFOLFOX chemotherapy for 12 courses, and their 5-year survival and tumor-free progression rates were recorded. Results The frequency of C/C and T/T＋C/T genotypes was 38.8% and 61.2%, respectively. The 5-year survival and tumor-free progression rates were 76.5% and 72.1% in patients with C/C genotype, and 53.8% and 46.1% in patients with T/T＋C/T genotype, respectively, and the difference was significant between both groups （P0.05）. Conclusion The patients with C/C genotype of ERCC1 may possess a good efficacy of oxaliplatin chemotherapy in stage Ⅲ colon adenocarcinoma.